Heartburn Clinical Trial
Official title:
Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in Gastroesophageal Reflux Disease(GERD)Patients With Severe Erosive Esophagitis(EE).
To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with Secretol 80/80 versus Nexium 40 mg daily.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | May 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Male or Female - Ages 18-75 - EE Los Angeles grades C or D - Heartburn and/or regurgitation at least 3 times a week during the 7 day run- in period prior to randomization. - Able to read, understand, and complete study questionnaires and record - Able to understand the study procedures and sign informed consent - Able to comply with all study requirements Exclusion Criteria: - Subjects with Barrett's esophagus, non-erosive reflux disease,EE grades A or B, or peptic stricture on endoscopy - Subjects with previous upper gastrointestinal surgery - Subjects with clinically significant underlying comorbidity - Helicobacter pylori positive - Clinically significant GI bleed within the last 3 months - Esophagitis not related to acid reflux - Bleeding disorder - Zollinger-Ellison, achalasia,esophageal varices, duodenal/gastric ulcer, upper gastrointestinal malignancy - Women pregnant or lactating - History of allergic reaction to any Proton Pump Inhibitor (PPI) - Patients can't be treated concurrently with warfarin or other anticoagulants,salicylates,steroids,NSAIDS > 3 times/week - Any medication dependant on gastric acid for optimal absorption |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Southern Arizona Veterans Health Care System | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
Effexus Pharmaceutical | Southern Arizona VA Health Care System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary objective is to evaluate the relationship between healing and study drug allotment. | The primary objective is to evaluate the relationship between healing and study drug allotment. The variables to be used are erosive esophagitis healing status after 3 weeks of treatment as assessed by EGD (upper endoscopy) comparing to base line EGD. | 3 weeks of treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06094062 -
Smartphone App-assisted PPI
|
N/A | |
Completed |
NCT00481949 -
Assessment of Gastro-esophageal Reflux Using Endo-Flip vs Bravo
|
N/A | |
Completed |
NCT04560595 -
Remote Guided Caffeine Reduction
|
N/A | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Recruiting |
NCT02105090 -
Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduodenoscopy
|
Phase 4 | |
Completed |
NCT01338077 -
Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease
|
Phase 3 | |
Completed |
NCT01005251 -
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
|
Phase 2 | |
Terminated |
NCT00536328 -
What is the Predictive Value of the Reflux Impact Scale
|
N/A | |
Completed |
NCT00382577 -
Efficacy and Safety of Itopride vs Placebo in Heartburn
|
Phase 3 | |
Completed |
NCT00236197 -
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
|
Phase 3 | |
Completed |
NCT00236184 -
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
|
Phase 3 | |
Completed |
NCT00236392 -
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
|
Phase 3 | |
Completed |
NCT04153552 -
Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn
|
N/A | |
Recruiting |
NCT06075082 -
The Effect of the LEFT Smartwatch App as Sleep Positional Therapy for Nocturnal Gastroesophageal Reflux Symptoms.
|
N/A | |
Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
Recruiting |
NCT02277886 -
Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances
|
Phase 4 | |
Completed |
NCT01249651 -
To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
|
Phase 4 | |
Completed |
NCT00588939 -
Confocal Laser Microscopy in Non Erosive Reflux Disease
|
N/A | |
Completed |
NCT00206024 -
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
|
Phase 4 | |
Recruiting |
NCT05976165 -
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
|
N/A |